Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Innate Pharma

Innate Pharma?uq=kzBhZRuG
1999 FOUNDED
PUBLIC STATUS
101-200 EMPLOYEES
IPH STOCK SYMBOL
2 INVESTMENTS
$5.43 SHARE PRICE (As of Friday Closing)
Description

Operator of a bio-pharmaceutical company intended to develop first-in-class therapeutic antibodies that harness the innate immune system. The company's bio-pharmaceutical process focuses on the development of therapeutic antibodies for the treatment of cancer and inflammatory diseases, enabling doctors to improve cancer treatment and clinical outcomes for patients.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Stock Exchange
PAR
Primary Office
  • 117, Avenue de Luminy
  • 30191 Marseille
  • France

+33 04 00 00 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Innate Pharma’s full profile, request a free trial.

Innate Pharma Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.19 - $13.46 $314M $5.45 -$1.00 141K

Innate Pharma Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 193,435 193,435 629,831 542,777
Revenue 36,800 36,800 62,121 19,864
EBITDA (49,069) (49,069) 18,061 (4,340)
Net Income (54,567) (54,567) 13,982 (7,439)
Total Assets 305,952 305,952 296,135 334,502
Total Debt 7,035 7,035 5,602 4,104
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Innate Pharma Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Innate Pharma‘s full profile, request access.

Request full access to PitchBook

Innate Pharma Investments (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 0000000 (0000 13-Jul-2017 000000000 00000 00 00000 Pharmaceuticals 0000000 00000000 00
Novo Nordisk (anti-NKG2A) 05-Feb-2014 Corporate Asset Purchase Buildings and Property 0000é 0000000 00.0
To view this company’s complete investment and acquisition history, request access »

Innate Pharma Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Innate Pharma‘s full profile, request access.

Request full access to PitchBook

Innate Pharma Executive Team (19)

Name Title Board
Seat
Contact
Info
Mondher Mahjoubi MD Chairman of the Executive Board & Chief Executive Officer
Marcel Rozencweig MD President, Executive Vice President and Chairman
Laure-Hélène Mercier Chief Financial Officer & Executive Vice President
Jerome Tiollier Ph.D Executive Vice President & Chief Development Officer
Nicolai Wagtmann Ph.D Member of the Executive Board & Chief Scientific Officer

2 Former Executives

You’re viewing 5 of 19 executives. Get the full list »

Innate Pharma Board Members (16)

Name Representing Role Since Contact
Info
Bernard Malissen Self Chairman of Scientific advisory Board 000 0000
David Raulet Ph.D Self Member of Scientific Advisory Board 000 0000
François Romagné Ph.D Innate Pharma Co-Founder & Member of Scientific Board 000 0000
Gilles Brisson Self Board Member 000 0000
Hervé Brailly Ph.D Innate Pharma Co-Founder & Chairman 000 0000

3 Former Board Members

You’re viewing 5 of 16 board members. Get the full list »